Related Experiment Video
Updated: Apr 7, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Liposomal Delivery Systems for Improved Delivery of Docetaxel Against Prostate Cancer
Joshua C Nwabuife1, Mamello P Sekhoacha1
1Discipline of Pharmacology, University of The Free State, Bloemfontein, 9301, South Africa.
None:
Generally, liposomes as a delivery system have been vastly designed for the delivery of therapeutic agents, to overcome various drawbacks, including resistance imposed to various conventional forms of these agents. They are significantly advantageous compared to other kinds of delivery systems because of their ability to deliver hydrophobic and hydrophilic therapeutic agents singly as monotherapy or combined as combinational therapy, owing to bilayer formation. Clinically, liposomes have been applied for delivery of therapeutic agents, with the aim of improving target-site-specificity and reducing toxicity to normal cells or tissues caused by chemotherapeutic drugs, which makes them relatively better options compared to the conventional forms of delivery system. Herein, a critical review which extensively discusses the various liposomal systems of delivery used for docetaxel (DTX) delivery against prostate cancer in the past decade, either alone as mono-therapeutical delivery or in combination with other therapeutic agents is presented. This review affirms to the potentials of employing liposomal systems of delivery for the effective targeted delivery of DTX against prostate cancer.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Bioavailability Enhancement: Drug Permeability Enhancement
Drug Delivery Systems: Different Types
Modified-Release Drug Delivery Systems: Classification
Modified-Release Drug Delivery Systems: Bioavailability

